A5084554493- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Organ Transplantation Techniques and Outcomes
- HIV, Drug Use, Sexual Risk
- HIV/AIDS drug development and treatment
- Global Cancer Incidence and Screening
- Healthcare Policy and Management
- Alcohol Consumption and Health Effects
- Hepatitis Viruses Studies and Epidemiology
- HIV/AIDS Research and Interventions
- Health disparities and outcomes
- Cardiovascular Health and Risk Factors
- Pancreatic and Hepatic Oncology Research
- Multiple and Secondary Primary Cancers
- Uterine Myomas and Treatments
- SARS-CoV-2 and COVID-19 Research
- Organ Donation and Transplantation
- Osteoarthritis Treatment and Mechanisms
- Neuroblastoma Research and Treatments
- Neuroendocrine Tumor Research Advances
- Multiple Myeloma Research and Treatments
- Long-Term Effects of COVID-19
University of Southern California
2019-2025
Los Angeles Medical Center
2023-2024
Keck Hospital of USC
2023
University of California, San Francisco
2016-2020
Center for Digestive and Liver Diseases
2020
Walter Reed National Military Medical Center
2019
Universidad Católica de Santa Fe
2019
Guangzhou Eighth People's Hospital
2015-2016
University of California, Los Angeles
2015
Background: Patients with cirrhosis and subcentimeter lesions on liver ultrasound are recommended to undergo short-interval follow-up because of the presumed low risk primary cancer (PLC). Aims: The aim this study is characterize recall patterns PLC in patients ultrasound. Methods: We conducted a multicenter retrospective cohort among or chronic hepatitis B infection who had between January 2017 December 2019. excluded history concomitant ≥1 cm diameter. used Kaplan Meier multivariable Cox...
Safety net systems care for patients with a high burden of liver disease yet experience many barriers to transplant (LT) referral. This study aimed assess safety providers' perspectives on LT referrals in the United States. We conducted nationwide anonymous online survey self-identified gastroenterologists and hepatologists from March through November 2022. 27-item was disseminated via e-mail, society platforms, social media. Survey sections included practice characteristics, referral...
Importance A high proportion of underserved patients with cirrhosis receive care at safety-net hospitals (SNHs). While liver transplant (LT) can be a life-saving treatment for cirrhosis, data on referral patterns from SNHs to LT centers are lacking. Objective To identify factors associated within the SNH context. Design, Setting, and Participants This retrospective cohort study included 521 adult model end-stage disease–sodium (MELD-Na) scores 15 or greater. received outpatient hepatology 3...
Patients with hepatocellular carcinoma (HCC) meeting UNOS-downstaging (DS) criteria have excellent post-liver transplantation (LT) outcomes. Studies on HCC beyond UNOS-DS ("All-comers" (AC)) been limited by small sample size and short follow-up time, prompting this analysis. 326 patients 190 AC from 9 LT centers across 5 UNOS regions were enrolled 2015 to 2023 prospectively followed. Competing risk analysis Kaplan-Meier method used evaluate downstaging outcomes, Fine-and-Gray Cox models...
Background: The RETREAT score is a simple risk stratification tool for post-liver transplantation (LT) hepatocellular carcinoma (HCC) recurrence that has been validated in retrospective cohort studies. A prospective, multicenter study needed to further demonstrate accuracy especially given evolving clinical demographics and HCC transplant practice. Aim: To validate compare the other post-LT scores contemporary, prospective of patients Approach: We prospectively enrolled from 8 centers...
Summary Background Chronic hepatitis B infection is an important contributor to mortality in the United States, yet impact of available and effective oral antivirals on among infected individuals unknown. Aims To compare risks predictors a recent time period between those with chronic, prior no infection. Methods This population‐based cohort study National Health Nutrition Examination Surveys participants 1999 2014 linked Death Index data. Adults aged 20 years or older serologic testing were...
HCC incidence varies by race/ethnicity. We characterized racial differences in underlying etiology, presentation, and survival the linkage of Multiethnic Cohort Study with SEER Medicare claims. characteristics, treatment, etiology participants were obtained. Deaths ascertained using state death certificates National Death Index. Risk factors collected via questionnaires. Cox models used to calculate hazard ratios (HR) 95% confidence intervals (CI) for death. Among 359 cases, average age at...
The World Health Organization recommends all men who have sex with (MSM) receive Hepatitis B Virus (HBV) and C (HCV) testing. MSM in China are a high-risk group for HBV HCV infection, but test uptake is low. Crowdsourcing invites large to solve problem then shares the solution public. This nationwide online randomized controlled trial will evaluate effectiveness of crowdsourced intervention increase testing among China.Seven hundred be recruited through social media operated by organizations...
Patients with hepatitis B early antigen (HBeAg)-negative chronic (CHB) and low-level viremia are a heterogeneous group. Identifying those at risk of developing active CHB requiring antiviral therapy is important. In this study, we prospectively characterize incidence rates predictors transitioning from inactive to in North American adult cohort.Participants the multicenter National Institute Diabetes Digestive Kidney Diseases Hepatitis Research Network cohort who were HBeAg negative baseline...
Abstract Country- and region-specific estimates of hepatitis B virus (HBV) screening, prevalence, immunity rates are provided for 202 868 adults from 174 unique countries in a large urban safety-net system. Of these, 41.8% (95% confidence interval, 41.5%–42.0%) were screened, with age-adjusted HBV prevalence 0.9% (.9%–1.0%); 55.3% (54.9%–55.7%) had testing, 32.4% (31.9%–33.0%) immune.